Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29395387 | 1.00 | CCR5 (1.00) | CCR5KCNH2 | |
| SCHEMBL4771825 | 0.94 | CCR5 (1.00) | CCR5 | |
| SCHEMBL18038094 | 0.91 | CCR5 (0.83) | CCR5KCNH2 | |
| SCHEMBL12531217 | 0.90 | CCR5 (0.86) | CCR5KCNH2 | |
| SCHEMBL4773696 | 0.90 | CCR5 (0.89) | CCR5KCNH2 | |
| SCHEMBL12531274 | 0.90 | CCR5 (0.89) | CCR5KCNH2 | |
| SCHEMBL12531355 | 0.90 | CCR5 (0.86) | CCR5KCNH2 | |
| SCHEMBL4775460 | 0.90 | CCR5 (0.86) | CCR5KCNH2 | |
| SCHEMBL3034563 | 0.90 | CCR5 (0.90) | CCR5KCNH2 | |
| SCHEMBL30227460 | 0.90 | CCR5 (0.90) | CCR5KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108561-A1 | COMPOSITION FOR CELL TRANSPLANTATION THERAPY AND THE USE THEREOF | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2026-04-23 | — | — | US | claimed |
| US-12440571-B2 | Immune agonists | SHENZHEN UNIVERSITY (CN) | 2025-10-14 | — | — | US | claimed |
| EP-4598598-A1 | COMPOSITION FOR CELL TRANSPLANTATION THERAPY AND THE USE THEREOF | National University of Singapore (SG) | 2025-08-13 | — | — | EP | claimed |
| US-20250170172-A1 | METHODS FOR TREATING LENTIVIRUS INFECTION | JERICHO SCIENCES LLC (US) | 2025-05-29 | — | — | US | claimed |
| WO-2024076303-A1 | COMPOSITION FOR CELL TRANSPLANTATION THERAPY AND THE USE THEREOF | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2024-04-11 | — | — | WO | claimed |
| WO-2023164293-A1 | METHODS FOR VIRAL INFECTIONS | JERICHO SCIENCES, LLC (US) | 2023-08-31 | — | — | WO | claimed |
| US-20230172912-A1 | COMPOUNDS FOR TREATING PNEUMONIA, SEPSIS, AND CORONAVIRUS INFECTION | HEIDELBERG IMMUNOTHERAPEUTICS GMBH (DE) | 2023-06-08 | — | — | US | claimed |
| US-20230108709-A1 | Immune Agonists | SHENZHEN UNIVERSITY (CN) | 2023-04-06 | — | — | US | claimed |
| EP-4132525-A1 | COMPOUNDS FOR TREATING PNEUMONIA, SEPSIS, AND CORONAVIRUS INFECTION | Heidelberg ImmunoTherapeutics GmbH (DE) | 2023-02-15 | — | — | EP | claimed |
| CN-107614515-B | T20 construct for anti-HIV (human immunodeficiency Virus) therapy and/or vaccine | 免疫医疗公司 | 2022-03-22 | — | — | CN | claimed |
| EP-1498138-A1 | PREVENTIVES FOR HIV INFECTION | Takeda Pharmaceutical Company Limited (JP) | 2005-01-19 | — | — | EP | claimed |
| US-20040053936-A1 | Medicinal composition for oral use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-18 | — | — | US | claimed |
| EP-1354587-A1 | MEDICINAL COMPOSITIONS FOR ORAL USE | Takeda Chemical Industries, Ltd. (JP) | 2003-10-22 | — | — | EP | claimed |
| US-20030114443-A1 | Cyclic amine compounds as CCR5 antagonists | TOBIRA THERAPEUTICS, INC. | 2003-06-19 | — | — | US | claimed |
| US-6562978-B1 | N-(3-(4-(4-(Aminocarbonyl)benzyl)-1-piperidinyl)propyl)-N-(3, 4-dichlorophenyl)-1-(methylsulfonyl)-4-piperidinecarboxamide or a salt thereof for treatment of AIDS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-05-13 | — | — | US | claimed |
| EP-1220842-A1 | CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS | Takeda Chemical Industries, Ltd. (JP) | 2002-07-10 | — | — | EP | claimed |
| EP-1147107-A4 | NOVEL ANGIOGENESIS INHIBITORS | MERCK & CO INC (US) | 2002-05-22 | — | — | EP | claimed |
| EP-1147107-A1 | NOVEL ANGIOGENESIS INHIBITORS | Merck & Co., Inc. (US) | 2001-10-24 | — | — | EP | claimed |
| WO-2001025200-A1 | CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-04-12 | — | — | WO | claimed |
| WO-2000043393-A1 | NOVEL ANGIOGENESIS INHIBITORS | MERCK & CO., INC. (US) | 2000-07-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250170172-A1 | METHODS FOR TREATING LENTIVIRUS INFECTION | ZC3HAV1, ZC3HAV1L, ZFR | CCR5 54/4885KCNH2 4589/4885 |
| US-20260108561-A1 | COMPOSITION FOR CELL TRANSPLANTATION THERAPY AND THE USE THEREOF | CCR5, CCRL2, CXCL12 | CCR5 1/4885KCNH2 3233/4885 |
| US-20230108709-A1 | Immune Agonists | TLR7, TLR3, TLR1 | CCR5 221/4885KCNH2 3856/4885 |
| US-12440571-B2 | Immune agonists | TLR7, TLR3, TLR1 | CCR5 221/4885KCNH2 3856/4885 |
| US-20030114443-A1 | Cyclic amine compounds as CCR5 antagonists | CCR5, CCR1, CCR3 | CCR5 1/4885KCNH2 174/4885 |
| US-20040053936-A1 | Medicinal composition for oral use | CCR5, CXCR3, CCL5 | CCR5 1/4885KCNH2 3882/4885 |
| US-20230172912-A1 | COMPOUNDS FOR TREATING PNEUMONIA, SEPSIS, AND CORONAVIRUS INFECTION | CCR5, CXCR3, CCL5 | CCR5 1/4885KCNH2 1013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.